Sanofi’s Lumizyme successor passes Phase 3 test in babies with Pompe disease

June 30, 2026 07:08 AM EDT R&DPharma Sanofi’s Pompe dis­ease treat­ment suc­ces­sor pass­es Phase 3 test in ba­bies Ayisha Sharma News Reporter Sanofi said its en­zyme re­place­ment ther­a­py suc­ceed­ed in a reg­is­tra­tional tri­al in a se­vere form of Pompe dis­ease, paving the way for a key la­bel … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER